KG
ACAD icon

Kilter Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Kilter Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47K Hold
58
– – ﹤0.01% 1149
2026
Q1 		$1.29K Hold
58
– – ﹤0.01% 1127
2025
Q4 		$1.55K Hold
58
– – ﹤0.01% 893
2025
Q3 		$1.24K Hold
58
– – ﹤0.01% 817
2025
Q2 		$1.25K Buy
+58
New +$1.08K ﹤0.01% 756

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kilter Group's ACAD Position: Q2 2026 in Review

Kilter Group held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 58 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #1149.

Kilter Group first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.55K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Kilter Group held 58 shares of Acadia Pharmaceuticals worth $1.47K as of Q2 2026.
  • Kilter Group left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1149 holding.
  • Kilter Group first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Kilter Group's Acadia Pharmaceuticals position peaked at $1.55K in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.